Evotec OAI Enters into Integrated Virtual Screening and Medici-nal Chemistry Agreement with Fujisawa

13-Apr-2004

Evotec OAI AG, a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, today announced that it has entered into an integrated virtual screening and medicinal chemistry collaboration with Fujisawa Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer in Japan, to identify, synthesise and optimise compounds that show biological activity against one of Fujisawa's drug targets.

A dedicated team of Evotec OAI chemists will work on this project in close collaboration with Fujisawa. Using integrated virtual screening and com-pound design software/expertise Evotec OAI will mine their chemical data-bases to identify and synthesise compounds that are predicted to be active against the target. Fujisawa will conduct biological screening of the com-pounds. In parallel, using Evotec OAI's state-of-the-art medicinal chemistry platform, these hits will be further optimised in terms of their potency, selec-tivity, in vitro ADMET and pharmacokinetic profile for the subsequent pro-gression into a lead optimisation programme.

Evotec OAI will receive fees for services carried out and milestone pay-ments for the successful achievement of predefined scientific results. Fi-nancial terms and Fujisawa's drug target were not disclosed.

Bernard Questier, Chief Business Officer of Evotec OAI, said: "We are extremely pleased and honoured to enter into this major collaboration with Fujisawa, a leading Japanese pharmaceutical company. This agreement demonstrates once again that our engagement and flexibility in integrating our technology platform supplements the drug discovery projects performed by companies in Japan, a market of significant importance to Evotec OAI."

https://www.bionity.com/en/news/36671/evotec-oai-enters-into-integrated-virtual-screening-and-medici-nal-chemistry-agreement-with-fujisawa.html